Fluroquinolone ppt

DESGIN ,SYNTHESIS AND BIOLOGICAL EVALUATION OF
FLUROQUINOLONE AND N N DONOR METAL COMPLEX.
M.Pharm. IInd YEAR. (Pharmaceutical Chemistry)
University Department Of Pharmaceutical Sciences,
Rashtrasant Tukadoji Maharaj Nagpur University, Nagpur
By
Mr. Dilip R. Davhare
Guide
Dr. P. M. Sable

Contents.
• Introduction…………………………………………………………………04
• History………………………………………………………………………….07
• Classification………………………………………………………………….09
• Metal complex………………………………………………………………12
• First generation drug…………………………………………………….18
• Second generation drug…………………………………………………24
• Third generation drug…………………………………………………….42
• Fourth generation drug………………………………………………….
• References…………………………………………………………………….
3

Quinolones
• The quinolones are a family of synthetic broad-spectrum antibiotics. The
term quinolone(s) refers to potent synthetic chemotherapeutic
antibacterial agent.
• The first generation of the quinolones begins with the introduction of
nalidixic acid in 1962 for treatment of urinary tract infections in humans.
Nalidixic acid was discovered by George Lesher and co-workers in a
distillate during an attempt at chloroquine synthesis.
• They prevent bacterial DNA from unwinding and duplicating 4

• The Fluoroquinolones are a
relatively new group of antibiotics.
Fluroquinolones were first
introduced in 1986, but they are
really modified quinolones, a class
of antibiotics, whose accidental
discovery occurred in the early
1960.
Fluoroquinolones
5

• The fluoroquinolones are a family of synthetic, broad-spectrum
antibacterial agents with bactericidal activity. The first
fluoroquinolones were widely used because they were the only
orally administered agents available for the treatment of
serious infections caused by gram-negative organisms,
including Pseudomonas species.
6

History
• The first quinolone was nalidixic acid introduced in 1962 for treatment
of urinary tract infections in humans. Nalidixic acid was discovered by
George Lesher and coworkers in a distillate during an attempt
at chloroquine synthesis. Nalidixic acid is thus considered to be the
predecessor of all members of the quinolone family, including the
second, third and fourth generations commonly known as
fluoroquinolones.
7

• This first generation also included other quinolone drugs, such
as pipemidic acid, oxolinic acid, and cinoxacin, which were introduced
in the 1970s. They proved to be only marginal improvements over
nalidixic acid.
• Since the introduction of nalidixic acid in 1962, more than
10,000 analogs have been synthesized, but only a handful have found
their way into clinical practice.
8

Classification
• Quinolones (1st generation)
• Highly protein bound
• Mostly used in UTIs
• Fluoroquinolones (2nd, 3rd and 4th generation)
• Modified 1st generation quinolones
• Not highly protein bound
• Wide distribution to urine and other tissues; limited CSF
penetration.
9

Generation Drug Names Spectrum
Nonfluorinated
Quinolone
nalidixic acid
Cinoxacin
rosoxacin
Gram- but not
Pseudomonas species.
First generation
Fluoroquinolones
norfloxacin
ciprofloxacin
enoxacin
ofloxacin
Gram- (including
Pseudomonas species),
some Gram+ (S. aureus)
and some atypicals.
10

Second
generation
Fluoroquinolones
levofloxacin
sparfloxacin
moxifloxacin
Gatifloxacin
moxifloxacin
Same as 2nd generation with
extended Gram+ and atypical
coverage.
Third generation
Fluoroquinolones
trovafloxacin
clinafloxacin
gemifloxacin
moxifloxacin
sitafloxacin
prulifloxacin
Same as 3rd generation with
broad anaerobic coverage
Fourth-generation
fluoroquinolones act at DNA
gyrase and topoisomerase IV.
This dual action slows
development of resistance.
11

Metal complex
• Medicinal applications of metals have played an important role in
medicine since thousands of years. Metal complexes or coordination
complexes, is an atom or ion (usually metallic), bonded to a
surrounding array of molecules or anions, which are in turn known as
ligands or complexing agents. Virtually all compounds containing
metals consist of coordination complexes.
12

Ligand based classification of metal
complexes
• The majority of ligands are anions or neutral molecules that function
as electronpair donors (Lewis base).
• Monodentate: Ligands that bind with a single donor atom to the
metal are called monodentate (“one-toothed” ligands)
: -F, -Cl, -Br, -CN, NH3, H2O
13

• Bidentate or polydentate: Ligands with two or more heteroatoms are
called bidentate or polydentate.
• 2,2'-Bipyridine Ethylenediamine Phenanthroline
14

Metal complex in cancer treatment
• The therapeutic use of metal complexes in cancer and leukemia are
reported from the sixteenth century.
• Metal complexes formed with other metals like copper, gold, gallium,
germanium, tin, ruthenium, iridium was shown significant antitumor
activity in animals
• In the treatment of ovarian cancer ruthenium compounds containing
arylazopyridine ligands show cytotoxic activity.
15

first-generation
The first-generation agents include cinoxacin and nalidixic acid, which are
the oldest and least often used quinolones. These drugs had poor
systemic distribution and limited activity and were used primarily for
gram-negative urinary tract infections. Cinoxacin and nalidixic acid
require more frequent dosing than the newer quinolones, and they are
more susceptible to the development of bacterial resistance.
16

Second Generation
The second-generation fluoroquinolones have increased gram-negative
activity, as well as some gram-positive and atypical pathogen coverage.
Compared with first-generation quinolones, these drugs have broader
clinical applications in the treatment of complicated urinary tract
infections and pyelonephritis, sexually transmitted diseases, selected
pneumonias and skin infections
17

Second-generation agents include ciprofloxacin, enoxacin, lomefloxacin,
norfloxacin and ofloxacin. Ciprofloxacin is the most potent
fluoroquinolone against P. aeruginosa. Ciprofloxacin and ofloxacin are the
most widely used second-generation quinolones because of their
availability in oral and intravenous formulations and their broad set of
FDA-labeled indications.
18

First generation drug
Cinoxacin
• Cinoxacin was an older synthetic
antimicrobial related to
the quinolone class of antibiotics
with activity similar to oxolinic
acid and nalidixic acid. It was
commonly used thirty years ago to
treat urinary tract infections in
adults.
(IUPAC) name
1-Ethyl-1,4-dihydro-4-
oxo[1,3]dioxolo[4,5-g]cinnoline-3-
carboxylic acid
19

History
• Cinoxacin is one of the original quinolone drugs, which were introduced
in the 1970s. Commonly referred to as the first generation quinolones.
• Cinoxacin was patented in 1972 and assigned to Eli Lilly. Eli Lilly obtained
approval from the FDA to market cinoxacin in the United States as
Cinobac on June 13, 1980. Prior to this cinobac was marketed in the U.K.
and Switzerland in 1979.
20

Mode of action
• Cinoxacin mode of action involves the inhibiting of DNA gyrase, a type
II topoisomerase, and topoisomerase iv, which is an enzyme
necessary to separate replicated DNA, thereby inhibiting cell division.
• Adverse reactions
• Hypersensitivity resulting in an anaphylactic reactions
21

Nalidixic acid
• It is a naphthyridone, not a
quinolone its ring structure is a
1,8-naphthyridine nucleus that
contains two nitrogen atoms,
unlike quinoline, which has a
single nitrogen atom.
(IUPAC) name
1-Ethyl-7-methyl-4-oxo-
[1,8]naphthyridine-3-
carboxylic acid
22

• Synthetic quinolone antibiotics were discovered by George Lesher and
coworkers as a byproduct of chloroquine manufacture in the 1960s. Used
clinically from 1967.
• Nalidixic acid is effective primarily against gram-negative bacteria, with
minor anti-gram-positive activity. In lower concentrations, it acts in
a bacteriostatic manner; that is, it inhibits growth and reproduction. In
higher concentrations, it is bactericidal, meaning that it kills bacteria
instead of merely inhibiting their growth.
23

• It has historically been used for treating urinary tract infections, caused,
for example, by Escherichia coli, Proteus, Shigella, Enterobacter,
and Klebsiella. It is no longer clinically used for this indication in the USA as
less toxic and more effective agents are available.
24

Second Generation Fluoroquinolone
Ciprofloxacin
• Second generation fluoroquinolone that was synthesized for first time
in 1987. A well known antibacterial drug with a wide spectrum of
activity, it is extremely useful for the treatment of a variety of
infections.
• Ciprofloxacin can usually act as a bidentate ligand through the
pyridone oxygen and one carboxylate oxygen
25

• Administration [Usual Dosage]: IV, PO [500 – 750 mg q 8-12h]
• Spectrum: Gram- aerobic rods, and Legionella pneumophila, and
other atypical. Poor activity against Strep. pneumoniae.
• Indications:
• Intra-abdominal infections
• Uncomplicated/complicated UTI
26

1- cyclopro-pyl-6-fluoro-1,4- dihydro-4-oxo-7- ( 1- piperaz- inil)- 3-
quinolone carboxylic acid
(IUPAC) name
27

Metal interacts with Cirofloxacin
• Ciprofloxacin with magnesium(Mg(II)), calcium(Ca(II)), and barium
(Ba(II)) increase antibacterial activity and decrease toxicity.
28

• Iztok Turel et al reported the complexation of Zn(II) ions with
quinolone in aqueous solution depending mainly upon pH. To
investigate the pH dependence of the complexation between Zn(II)
and the quinolone derivative ciprofloxacin (cfH), UV-Vis spectroscopy
was used.
29

Norfloxacin
• Norfloxacin is synthetic chemotherapeutic antibacterial agent
occasionally used to treat common as well as complicated urinary tract
infections.
(IUPAC) name
1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1H-quinoline-
3-carboxylic acid 30

History
• In 1979 the publication of a patent filed by the pharmaceutical arm
of Kyorin Seiyaku Kabushiki Kaisha disclosed the discovery of norfloxacin,
and the demonstration that certain structural modifications including the
attachment of a fluorine atom to the quinolone ring leads to dramatically
enhanced antibacterial potency.
31

Mode of action
• Norfloxacin is a broad-spectrum antibiotic that is active against
both Gram-positive and Gram-negative bacteria. It functions by
inhibiting DNA gyrase, a type topoisomerase II, and topoisomerase
IV, enzymes necessary to separate bacterial DNA, thereby inhibiting
cell division. Norfloxacin does not bind to DNA gyrase but does bind
to the substrate DNA.
32

Synthesis
1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1H-quinoline-
3-carboxylic acid
33

Ofloxacin
• Ofloxacin is a racemic mixture, which consists of 50% levofloxacin (the
biologically active component) and 50% of its “mirror image” or
enantiomer dextrofloxacin.
• Ofloxacin was first patented in 1982 (European Patent Daiichi) and
received approval from the U.S. Food and Drug Administration(FDA) on
December 28, 1990.
34

(IUPAC) name
(RS)-7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-
oxa-1-azatricyclo[7.3.1.0
5,13
]trideca-5(13),6,8,11-tetraene-11-
carboxylic acid
35

36
• Mode of action
• Ofloxacin is a broad-spectrum antibiotic that is active against
both Gram-positive and Gram-negative bacteria. It functions by
inhibiting DNA gyrase, a type II topoisomerase, and topoisomerase
IV, which is an enzyme necessary to separate (mostly in prokaryotes,
in bacteria in particular) replicated DNA, thereby inhibiting bacterial
cell division.

37
Pefloxacin
(IUPAC) name
1-ethyl-6-fluoro-7-(4-methylpiperazin-1-yl)-4-oxo-quinoline-3-carboxylic
acid

• History:-
Pefloxacin was developed in 1979 and approved in France for human use in
1985.
• Mode of action:-
Pefloxacin is a broad-spectrum antibiotic that is active against both Gram-
positive and Gram-negative bacteria. It functions by inhibiting DNA gyrase, a
type topoisomerase II, and topoisomerase IV, which is an enzyme necessary to
separate, replicated DNA, thereby inhibiting cell division.
38

39
Nadifloxacin
• Nadifloxacin is a topical fluoroquinolone antibiotic for the treatment
of acne vulgaris. It is also used to treat bacterial skin infections.
• (IUPAC) name:-
(RS)-9-Fluoro-8-(4-hydroxy-piperidin-1-yl)-5-methyl-1-oxo-6,7-
dihydro-1H,5H-pyrido[3,2,1-ij]quinoline-2-carboxylic acid.

40
• Antibacterial spectrum
• In vitro studies of nadifloxacin showed potent and broad-spectrum antibacterial
activity against aerobic Gram-positive, Gram-negative and anaerobic bacteria,
including Propionibacterium acnes and Staphylococcus epidermidis.
Nadifloxacin showed potent antibacterial activity against methicillin-
resistant Staphylococcus aureus (MRSA), which was similar to potency
against methicillin-sensitive Staphylococcus aureus (MSSA). The drug was also
active against new quinolone-resistant MRSA. Nadifloxacin does not show
cross-resistance with other new quinolones.

41
• Mechanism of action
• Nadifloxacin inhibits the enzyme DNA gyrase that is involved in
bacterial DNA synthesis and replication, thus inhibiting the bacterial
multiplication. Nadifloxacin in addition to determine a therapeutic
antibacterial action, can have a sebostatic and anti-inflammatory
action, thus contributing to the improvement of the clinical condition
of the patient.

Third-generation
Levofloxacin
• IUPAC) name
(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-
7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid 42

• Levofloxacin is the levo isomer of the racemate ofloxacin, another
quinolone antimicrobial agent. In layman terms, this means that
levofloxacin is the 50% of ofloxacin that have been found to be effective
against bacteria, while the other 50% have been removed. In chemical
terms, levofloxacin, a chiral fluorinated carboxyquinolone, is the pure (−)-
(S)-enantiomer of the racemic ofloxacin.
• The substance is used as the hemihydrate, which has the empirical formula
C18H20FN3O4 · ½ H2O and a molecular mass of 370.38 g/mol. Levofloxacin is
a light-yellowish-white to yellow-white crystal or crystalline powder.
43

Mechanism of action
• Like all quinolones, it functions by inhibiting the two type topoisomerase
II enzymes, namely DNA gyrase and topoisomerase IV. Topoisomerase IV
is necessary to separate DNA that has been replicated (doubled) prior to
bacterial cell division. With the DNA not being separated, the process is
stopped, and the bacterium cannot divide. DNA gyrase, on the other
hand, is responsible for supercoiling the DNA, so that it will fit in the
newly formed cells.
44

Grepafloxacin
• (IUPAC) name
(RS)-1-cyclopropyl-6-fluoro-5-methyl-7-(3-methylpiperazin-1-yl)- 4-
oxo-quinoline- 3-carboxylic acid.
45

46
• Grepafloxacin hydrochloride was an oral broad-
spectrum fluoroquinolone antibacterial agent used to
treat bacterial infections. Grepafloxacin was withdrawn worldwide
from markets in 1999, owing to its side effect of lengthening the QT
interval on the electrocardiogram, leading to cardiac events
and sudden death.

48
• The preparation of quinolones bearing a substituent at position 5 is
complicated by the greater electrophilic character of the 8 position. One
scheme for resolving the problem consists in blocking access to position 8 by
first adding a readily removable group to that center.
• he scheme starts with the conversion of the carboxylic acid in (1) to its
dimethyloxazoline derivative (3) by reaction with the dimethyl ethanolamine
(2). Lithium diisopropylamide (LDA) then removes a proton from the 8 position;
treatment of that anion with trimethylsilyl iodide leads to the silylated
intermediate (4).

49
• A second round of LDA then generates a carbanion at the only open
position; reaction with methyl iodide leads to the corresponding 5 methyl
derivative (5). Treatment of that product with cesium fluoride breaks the
carbon–silicon bond, removing the silyl group aqueous acid then hydrolyzes
the oxazoline to afford the free acid (6). This last intermediate is then taken
on to the quinolone (9) by essentially the same scheme as that used to
prepare difloxacin, with the difference that the chain elongation is by
means of Grignard reagent of Ethyl bromoacetate. Treatment of (9) with 2-
methylpiperazine proceeds by reaction at the less hindered of the two
amino groups; saponification then affords grepafloxacin (10).

• osufloxacin is a fluoroquinolone antibiotic. It has a controversial
safety profile in relation to other fluoroquinolones. It is associated
with severe thrombocytopenia and nephritis, and hepatotoxicity.[1] It
is sold in Japan under the brand name Ozex.
• See also[edit]
51

Sparfloxacin
• (IUPAC) name
5-Amino-1-cyclopropyl-7-[(3R,5S)3,5-dimethylpiperazin-1-yl]-6,8-
difluoro-4-oxo-quinoline-3-carboxylic acid
52

Reference’s
• Prafulla M. Sabale, Jahanvi Patel and Yogini Patel, Metal complexes:
current trends and future potential, ISSN: 2249-9504.
• Drlica K, Zhao X; Zhao (1 September 1997). "DNA gyrase, topoisomerase
IV, and the 4-quinolones". Microbiol Mol Biol Rev. 61 (3): 377–
92. PMC 232616. PMID 9293187.
• KD. Tripathi, Essential of medicinal pharmaology, sixth edition, JAYPEE
Publication. Page no. 687-93.
54

Fluroquinolone ppt

More Related Content

What's hot (20)

Viewers also liked (20)

Similar to Fluroquinolone ppt (20)

Recently uploaded (20)

Fluroquinolone ppt